Haemonetics Learns the Hard Way
After a failed excursion into the blood banking business, Haemonetics tries to get back on track by returning to its core business of manufacturing blood collection and blood salvage devices. Underestimating the perils of running blood collection centers, Haemonetics found itself diverting resources from its device business and alienating the customers with whom it now competed. A new management team is divesting the blood centers, refocusing on developing new products, and working to mend fences with former customers such as the Red Cross.
You may also be interested in...
Data from the first 275 patients in the trial are promising, but outside experts say they are wary of another hasty Emergency Use Authorization.
European Commission medtech news all but dried up in September. But the UK’s Brexit news and implications for medtech has given EU and UK medtech stakeholders enough to ponder.
A new frontier for IO therapies in gastric/gastroesophageal cancers is opening up on positive data for two leading checkpoint inhibitors in first-line advanced disease where BMS’s Opdivo looks likely to have an advantage over Merck & Co’s Keytruda.